Slide 1: Sight Sciences Investor Presentation November 2025
Sight Sciences Investor Presentation November 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act o
Slide 3: Sight Sciences Mission
[[ Sight Sciences Mission Develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care — empowering people to keep seeing. | 3
Slide 4: A Glimpse Ahead
A Glimpse Ahead Innovation leader in two large, growing, underserved markets 1 TearCare market access has started with first 2 MACs establishing fee schedules Oct 2025 2 Strong balance sheet supports investments in R&D pipeline, clinical and commercial infrastructure 3 Healthy gross margin and disci
Slide 5: The Path to Early Intervention
A strategic roadmap to transform eyecare for glaucoma and dry eye patients by reducing patient burden, slowing disease progression, and improving outcomes. Embrace intervention as a better alternative to medication management Shift the care continuum to address underlying disease over symptom manage
Slide 6: Glaucoma
EZ a” Glaucoma —
Slide 7: Glaucoma: Large + Underserved Markets
Glaucoma Leading cause of irreversible blindness1 Predominantly managed with daily eye drops (compliance often poor)2 Normal Mild Moderate Severe Large + Underserved Markets ¹ Source: Market Scope 2024 report and JAMA Ophthalmology Prevalence of Glaucoma Among US Adults in 2022 Oct 17, 2024 . ² Newm
Slide 8: POAG is similar to a clog in a kitchen sink
POAG is similar to a clog in a kitchen sink: 01 TRABECULAR MESHWORK 02 SCHLEMM‘S CANAL 03 COLLECTOR CHANNELS 01 02 03 THE CONVENTIONAL OUTFLOW PATHWAY IS AN IMPORTANT FOCAL POINT IN TREATING POAG, THE MOST COMMON FORM OF GLAUCOMA. The eye’s natural drainage system is called the conventional outflow
Slide 9: Effective + Intuitive Intervention
Effective + Intuitive Intervention OUR FLAGSHIP TECHNOLOGY SURGICAL GLAUCOMA Offering a comprehensive intervention that drives leading clinical outcomes for Primary Open-Angle Glaucoma (POAG) ¹ Estimate based on units of OMNI (and predicates) and SION products shipped as of September 30, 2025 Compre
Slide 10: OMNI Comprehensively Treats the Conventional Outflow Pathway
OMNI Comprehensively Treats the Conventional Outflow Pathway Minimally Invasive + Efficacious A comprehensive procedure enabled by the OMNI® Surgical System to help restore natural outflow in the eye with up to 360° treatment of all three areas of resistance* in the conventional outflow pathway * Tr
Slide 11: OMNI is Proven with Robust Clinical Evidence & Broad FDA Indication
OMNI is Proven with Robust Clinical Evidence & Broad FDA Indication AGIS-7 Findings3 <18 mmHg is the target IOP to limit the progression of glaucoma. On average, there was zero change in visual field defect score for patients whose IOP stayed below 18 mmHg over 6 years. OMNI is the most comprehensiv
Slide 12: Consistent Efficacy of OMNI in Combination Cataract and Standalone
Consistent Efficacy of OMNI in Combination Cataract (CC) and Standalone (SA) Clinical Trials COMBINATION CATARACT STANDALONE EFFICACY DEMONSTRATED OUT TO 3 YEARS GEMINI (12 Months)* ROMEO Elevated IOP CC (24 Months) ROMEO Elevated IOP SA (24 Months) TREY SA (11 Months)* GEMINI 2 IOP Outcomes CC (36
Slide 13: OMNI Addresses All Six MIGS POAG Categories
OMNI Addresses All Six MIGS POAG Categories Allows surgeons to customize treatment ¹ Represents Company analysis of third-party estimates based on 2024 data MILD DISEASE (40%) MODERATE DISEASE (40%) ADVANCED DISEASE (20%) ~$2B opportunity ~$2B opportunity ~$1B opportunity ~$0.4B opportunity ~$0.4B o
Slide 14: Large and Unmet Clinical Need for Standalone MIGS
Large and Unmet Clinical Need for Standalone MIGS Combination Cataract Standalone | 14 <15% of POAG eyes1, >90% of MIGS procedures2 Established, growing market Benefits from inherent IOP-lowering effect of cataract surgery Share-taking driven by efficacy, fast recovery times and attractive safety pr
Slide 15: MIGS for the Pseudophakic Patient
MIGS for the Pseudophakic Patient The Glaucoma Patient Journey1 1 ESCRS. “Glaucoma Treatment Paradigm Shift.” By Dr. Karl Mercieca. EuroTimes. 2 SLT is Selective Laser Trabeculoplasty . Zone of unmet clinical need Pseudophakic POAG Patients 3-7 yrs post-op Glaucoma Diagnosis Patient diagnosed with g
Slide 16: Standalone Market Development is Underway
Standalone Market Development is Underway Claims data indicate increasing usage of codes associated with OMNI1 for billing of standalone procedures OMNI technology meets enhanced efficacy and safety needs for standalone procedures ROMEO ROMEO two-year extension TREY Sole purpose of OR visit – degree
Slide 17: Surgical Glaucoma Pipeline
Implantable Canalicular Scaffold (MIGS)* 01 Suprachoroidal Implant (MIGS)* 02 Sustained Release Pharmaceutical (Rx)* 03 CURRENT PRODUCTS IN THE PIPELINE *This pipeline product is under development and is not commercially available. The Company may suspend or discontinue pipeline development projects
Slide 18: Dry Eye Disease
EZ a” Dry Eye Disease was
Slide 19: Dry Eye Disease: Large + Underserved Markets
Dry Eye Disease Linked to screen time, age (postmenopausal women, men 50+), systemic medication use Predominantly managed with daily eye drops (compliance often poor)1 Normal Mild Moderate Severe Large + Underserved Markets $1.7 billion US market for dry eye treatments 2 >19.4 million U.S. patients
Slide 20: Overview: Tears and Meibomian Gland Disease (MGD)
Overview: Tears and Meibomian Gland Disease (MGD) TEAR FILM ANATOMY MEIBOMIAN GLANDS Tears consist of three layers Outermost layer consists of oily substance called meibum Coats and protects inner layers Prevents premature evaporation Healthy meibomian glands release liquid meibum with each blink In
Slide 21: A new order of care: The case for TearCare
A new order of care Effective intervention shouldn’t wait, because meibomian gland dropout is irreversible and critical to ocular surface health1-3 TearCare targets the root cause of MGD: obstructed glands with demonstrated improvement of meibomian gland function4 SAHARA Results: TearCare was clinic
Slide 22: MGD Opportunity
MGD Opportunity U.S. patients diagnosed with Dry Eye Disease (DED) 1 Million DED patients 19.4 Up to 86% of DED is associated with poor tear quality due to MGD 1, 2 Million MGD patients 13.6 – 16.7 ~50% of DED patients have moderate to severe symptoms 1 (most likely to seek treatment + targeted pati
Slide 23: MGD is an Underserved Disease State
MGD is an Underserved Disease State The current market is dominated by eyedrops that do not address the underlying causes of MGD 1 Many dry eye treatments focus on increasing tear volume in aqueous deficient patients No interventional standard of care for treatment of MGD There is poor patient compl
Slide 24: Targeted + Intuitive Intervention
Targeted + Intuitive Intervention OUR TECHNOLOGIES DRY EYE Offering a comprehensive therapy intervention that drives leading clinical outcomes for evaporative dry eye disease ¹ Estimate based on Dry Eye Treatment Lids shipped as of September 30, 2025. Comprehensive therapy to treat diseased meibomia
Slide 25: TearCare: Designed to Preserve and Improve Gland Functionality
TearCare: Designed to Preserve and Improve Gland Functionality TearCare is the only FDA-cleared interventional, open-eye, thermal-activated gland expression therapy designed to treat MGD conveniently and comfortably ¹ Gupta et al. Cornea 2022;41:417–426 Thin, wearable SmartLids® conform to the eyeli
Slide 26: SAHARA RCT
SAHARA RCT Randomized Controlled Trial comparing TearCare and Restasis®1 Signs Superiority + Durability 2 + Head-to-Head Study TearCare vs Restasis1 + Large Trial (N=345) + Randomized + Assessor Masked + 3 Stages + Long-term (2-year trial) ¹ Restasis is a trademark of Allergan™ an AbbVie company ² E
Slide 27: SAHARA RCT: Results
SAHARA RCT: Results ¹ Endpoints for SAHARA include superiority over Restasis at six months in our primary objective endpoint, tear break-up time. TearCare treatment at Baseline and Month 5, Restasis twice a day for six months. Study through 24 months to show duration of effectiveness. ² Restasis is
Slide 28: SAHARA RCT: Results
SAHARA RCT: Results ¹ 66% of TearCare® patients experienced dry eye relief for 2 years from study baseline. Study baseline refers to assessment at the start of SAHARA prior to any treatment and 5 months prior to the start of the Stage 3 durability stage. Months are measured from Study Baseline. Erro
Slide 29: TearCare Strategy: Targeted + Scalable Growth
TearCare Strategy: Targeted + Scalable Growth ¹ Estimated as of June 30, 2025 based on review of claims data and Company analytics 2 As of September 30, 2025 Actively Engaging in Pursuit of Equitable Market Access With the power of TearCare, we can: Improve the lives of U.S. MGD patients Scale comme
Slide 30: Annual Revenue and Gross Margin %
Annual Revenue and Gross Margin % SGHT DRY EYE SURGICAL GLAUCOMA GROSS MARGIN % $27.6 $1.6 $26.0 $49.0 $2.5 $46.5 $71.3 $5.7 $65.6 $81.1 $6.7 $74.3 $76.0M - $78.0M1 $79.9 $4.0 $75.9 +30% FY24 Gross Margin % Revenue CAGR FY20 to FY24 FY25 Guidance Revenue $76M - $78M¹ Adj. OpEx² 90M - $92M¹ 85.5% 87.
Slide 31: Strategic Value Creation Initiatives Represent Sustainable Growth Drivers
Strategic Value Creation Initiatives Represent Sustainable Growth Drivers Expand OMNI Utilization TearCare Access + Expansion Certify new OMNI surgeons Gain share in combination cataract segment Develop the standalone pseudophakic MIGS segment Generate additional clinical evidence Enhance coverage a
Slide 32: Why Now?
Why Now? Innovation leader in two large, growing, underserved markets 1 TearCare market access has started with first 2 MACs establishing fee schedules Oct 2025 2 Strong balance sheet supports investments in R&D pipeline, clinical and commercial infrastructure 3 Strong gross margin and disciplined o
Slide 33: Thank you!
Thank you! If you have any questions, please contact investor.relations@sightsciences.com © 2025 Sight Sciences and/or certain of its affiliates, All rights reserved. Sight Sciences, the Sight Sciences logo, OMNI, SION, TearCare, and TruSync are trademarks or registered trademarks of Sight Sciences.